# A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

> **NCT01789736** · PHASE2 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 234 (actual)

## Conditions studied

- Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** PG286 Ophthalmic Solution 0.5%
- **DRUG:** AR-12286 Ophthalmic Solution 0.5%
- **DRUG:** Travoprost Ophthalmic Solution 0.004%

## Key facts

- **NCT ID:** NCT01789736
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2014-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01789736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01789736, "A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01789736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*